Elucidation of the structure of talinolol metabolites in man. Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum.
The objective of this study was to determine the structure of talinolol metabolites formed and the amounts excreted in urine. Talinolol metabolites in urine were identified by comparing their HPLC retention times and their GC-MS profile with those of previously characterized reference compounds. The metabolites were quantified by HPLC with a normal-phase silica column, a single chloroform extraction and UV detection. Less than 1% of an administered dose was found in urine as hydroxylated talinolol. Other metabolites could be excluded. A sensitive method to determine talinolol in serum and a simple method for analysis of talinolol in urine are described. These methods were found to be precise and accurate for the measurement of talinolol in samples obtained from patients during chronic talinolol treatment as well as from healthy volunteers after a single dose of talinolol.
Oertel
R
R
Institute of Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Technical University Dresden, Germany.
Richter
K
K
Trausch
B
B
Berndt
A
A
Gramatté
T
T
Kirch
W
W
D000319:Adrenergic beta-Antagonists / Q000032:analysis* / Q000097:blood / Q000652:urine; D000328:Adult; D002851:Chromatography, High Pressure Liquid; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D006900:Hydroxylation; D007536:Isomerism; D011412:Propanolamines / Q000032:analysis* / Q000097:blood / Q000652:urine; D013056:Spectrophotometry, Ultraviolet
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; C011550:talinolol